Detalhe da pesquisa
1.
Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.
Gastric Cancer
; 27(1): 131-145, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37964032
2.
Is there a preferred platinum and fluoropyrimidine regimen for advanced HER2-negative esophagogastric adenocarcinoma? Insights from 1293 patients in AGAMENON-SEOM registry.
Clin Transl Oncol
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38361134
3.
The AGAMENON-SEOM model for prediction of survival in patients with advanced HER2-positive oesophagogastric adenocarcinoma receiving first-line trastuzumab-based therapy.
Ther Adv Med Oncol
; 15: 17588359231157641, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36895850